Cargando…
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
BACKGROUND: Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant chemotherapy further improved survival compared with the current standard regim...
Autores principales: | Alderson, Derek, Cunningham, David, Nankivell, Matthew, Blazeby, Jane M, Griffin, S Michael, Crellin, Adrian, Grabsch, Heike I, Langer, Rupert, Pritchard, Susan, Okines, Alicia, Krysztopik, Richard, Coxon, Fareeda, Thompson, Joyce, Falk, Stephen, Robb, Clare, Stenning, Sally, Langley, Ruth E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lancet Pub. Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585417/ https://www.ncbi.nlm.nih.gov/pubmed/28784312 http://dx.doi.org/10.1016/S1470-2045(17)30447-3 |
Ejemplares similares
-
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009) -
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial
por: Hale, Matthew D., et al.
Publicado: (2016) -
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial
por: Davarzani, Nasser, et al.
Publicado: (2018) -
Prognostic Significance of Negative Lymph Node Long Axis in Esophageal Cancer: Results From the Randomized Controlled UK MRC OE02 Trial
por: Kloft, Maximilian, et al.
Publicado: (2023) -
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)